test

E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy (ECOG 7208)

Conditions

Colon

What is the purpose of this trial?


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Eastern Cooperative Oncology Group
Dates:
01/15/2011
Last Updated:
Study HIC#:
1010007561